Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Technical Development of a New Meningococcal Conjugate Vaccine.

Frasch CE, Kapre SV, Lee CH, Préaud JM.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S404-9. doi: 10.1093/cid/civ595. Review.

2.

Description and nomenclature of Neisseria meningitidis capsule locus.

Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, Corton C, Care R, Poolman JT, Zollinger WD, Frasch CE, Stephens DS, Feavers I, Frosch M, Parkhill J, Vogel U, Quail MA, Bentley SD, Maiden MC.

Emerg Infect Dis. 2013 Apr;19(4):566-73. doi: 10.3201/eid1904.111799.

3.

Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM).

Frasch CE, Preziosi MP, LaForce FM.

Hum Vaccin Immunother. 2012 Jun;8(6):715-24. doi: 10.4161/hv.19619. Epub 2012 Apr 12. Review.

PMID:
22495119
4.

Capsular serotype of Staphylococcus aureus in the era of community-acquired MRSA.

Sutter DE, Summers AM, Keys CE, Taylor KL, Frasch CE, Braun LE, Fattom AI, Bash MC.

FEMS Immunol Med Microbiol. 2011 Oct;63(1):16-24. doi: 10.1111/j.1574-695X.2011.00822.x. Epub 2011 Jul 18.

5.

Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines.

Poolman JT, Frasch CE, Käyhty H, Lestrate P, Madhi SA, Henckaerts I.

Clin Vaccine Immunol. 2010 Jan;17(1):134-42. doi: 10.1128/CVI.00289-09. Epub 2009 Nov 4.

6.

Preparation of bacterial polysaccharide-protein conjugates: analytical and manufacturing challenges.

Frasch CE.

Vaccine. 2009 Oct 30;27(46):6468-70. doi: 10.1016/j.vaccine.2009.06.013. Epub 2009 Jun 24. Review.

PMID:
19555714
7.

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease.

Frasch CE, Borrow R, Donnelly J.

Vaccine. 2009 Jun 24;27 Suppl 2:B112-6. doi: 10.1016/j.vaccine.2009.04.065. Epub 2009 May 21. Review.

PMID:
19464093
8.

Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa.

Lee CH, Kuo WC, Beri S, Kapre S, Joshi JS, Bouveret N, LaForce FM, Frasch CE.

Vaccine. 2009 Jan 29;27(5):726-32. doi: 10.1016/j.vaccine.2008.11.065. Epub 2008 Dec 6.

PMID:
19063929
9.
10.

Characterization and immunogenicity of meningococcal group C conjugate vaccine prepared using hydrazide-activated tetanus toxoid.

Silveira IA, Bastos RC, Neto MS, Laranjeira AP, Assis EF, Fernandes SA, Leal ML, Silva WC, Lee CH, Frasch CE, Peralta JM, Jessouroun E.

Vaccine. 2007 Oct 10;25(41):7261-70. Epub 2007 Aug 7.

PMID:
17719147
11.

Differential capacities of outer membrane proteins from Neisseria meningitidis B to prime the murine immune system after vaccination.

Silva Junior FC, Gioia CA, Oliveira JM, Cruz SC, Frasch CE, Milagres LG.

Scand J Immunol. 2007 Jan;65(1):1-7.

12.

Phylogenetic lineages of invasive and colonizing strains of serotype III group B Streptococci from neonates: a multicenter prospective study.

Lin FY, Whiting A, Adderson E, Takahashi S, Dunn DM, Weiss R, Azimi PH, Philips JB 3rd, Weisman LE, Regan J, Clark P, Rhoads GG, Frasch CE, Troendle J, Moyer P, Bohnsack JF.

J Clin Microbiol. 2006 Apr;44(4):1257-61.

13.

Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines.

Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D, Nahm MH.

Clin Vaccine Immunol. 2006 Feb;13(2):165-9. Review. No abstract available.

14.

Effect of a booster dose of serogroup B meningococcal vaccine on antibody response to Neisseria meningitidis in mice vaccinated with different immunization schedules.

Gioia CA, de Sousa AB, Cruz SC, Junior FC, Andrade AF, Sassi RM, Frasch CE, Milagres LG.

FEMS Immunol Med Microbiol. 2005 Apr 1;44(1):35-42.

15.

Recent developments in Neisseria meningitidis group A conjugate vaccines.

Frasch CE.

Expert Opin Biol Ther. 2005 Feb;5(2):273-80. Review.

PMID:
15757388
16.

Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations.

Mikolajczyk MG, Concepcion NF, Wang T, Frazier D, Golding B, Frasch CE, Scott DE.

Clin Diagn Lab Immunol. 2004 Nov;11(6):1158-64.

17.

Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen.

Lin FY, Weisman LE, Azimi PH, Philips JB 3rd, Clark P, Regan J, Rhoads GG, Frasch CE, Gray BM, Troendle J, Brenner RA, Moyer P, Clemens JD.

J Infect Dis. 2004 Sep 1;190(5):928-34. Epub 2004 Jul 28.

PMID:
15295698
18.

Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.

Jessouroun E, da Silveira IF, Larangeira AP, Pereira S, Fernandes SA, Rabinovitch L, Frasch CE, Castro-Faria-Neto HC, Bozza PT.

Vaccine. 2004 Jun 30;22(20):2617-25.

PMID:
15193387
19.

Protective immunity of pneumococcal glycoconjugates.

Lee CJ, Lee LH, Frasch CE.

Crit Rev Microbiol. 2003;29(4):333-49. Review.

PMID:
14636043
20.

Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.

Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, Benjamin W, Quataert SA, Hildreth S, Sikkema DJ, Käyhty H, Jonsdottir I, Nahm MH.

Clin Diagn Lab Immunol. 2003 Jul;10(4):514-9. Review. No abstract available.

21.

Correlates of immunity for pneumococcal conjugate vaccines.

Lee LH, Frasch CE, Falk LA, Klein DL, Deal CD.

Vaccine. 2003 May 16;21(17-18):2190-6. Review.

PMID:
12706710
22.

High burden of invasive Streptococcus agalactiae disease in South African infants.

Madhi SA, Radebe K, Crewe-Brown H, Frasch CE, Arakere G, Mokhachane M, Kimura A.

Ann Trop Paediatr. 2003 Mar;23(1):15-23.

PMID:
12648320
23.

Immune response to native NadA from Neisseria meningitidis and its expression in clinical isolates in Brazil.

Fukasawa LO, Gorla MC, Lemos AP, Schenkman RP, Brandileone MC, Fox JW, Raw I, Frasch CE, Tanizaki MM.

J Med Microbiol. 2003 Feb;52(Pt 2):121-5.

PMID:
12543917
24.
25.
26.

Development and evaluation of pneumococcal conjugate vaccines: clinical trials and control tests.

Lee LH, Lee CJ, Frasch CE.

Crit Rev Microbiol. 2002;28(1):27-41. Review.

PMID:
12003039
27.

Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study.

Lin FY, Philips JB 3rd, Azimi PH, Weisman LE, Clark P, Rhoads GG, Regan J, Concepcion NF, Frasch CE, Troendle J, Brenner RA, Gray BM, Bhushan R, Fitzgerald G, Moyer P, Clemens JD.

J Infect Dis. 2001 Oct 15;184(8):1022-8. Epub 2001 Aug 31.

PMID:
11574917
29.
30.

Immunogenicity in mice of pneumococcal glycoconjugate vaccines using pneumococcal protein carriers.

Lee CJ, Wang TR, Frasch CE.

Vaccine. 2001 Apr 30;19(23-24):3216-25.

PMID:
11312018
32.

Outer membrane protein vesicle vaccines for meningococcal disease.

Frasch CE, van Alphen L, Holst J, Poolman JT, Rosenqvist E.

Methods Mol Med. 2001;66:81-107. doi: 10.1385/1-59259-148-5:81.

PMID:
21336749
33.

Genetic and immunologic characterization of a novel serotype 4, 15 strain of Neisseria meningitidis.

Bash MC, Lynn F, Concepcion NF, Tappero JW, Carlone GM, Frasch CE.

FEMS Immunol Med Microbiol. 2000 Nov;29(3):169-76.

34.

An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study.

Plikaytis BD, Goldblatt D, Frasch CE, Blondeau C, Bybel MJ, Giebink GS, Jonsdottir I, Käyhty H, Konradsen HB, Madore DV, Nahm MH, Schulman CA, Holder PF, Lezhava T, Elie CM, Carlone GM.

J Clin Microbiol. 2000 Jun;38(6):2043-50.

35.

Specificity of human antibodies reactive with pneumococcal C polysaccharide.

Frasch CE, Concepcion NF.

Infect Immun. 2000 Apr;68(4):2333-7.

37.

Inhibition enzyme-linked immunosorbent assay for serotyping of group B streptococcal isolates.

Arakere G, Flores AE, Ferrieri P, Frasch CE.

J Clin Microbiol. 1999 Aug;37(8):2564-7.

38.
39.

Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature.

Sacchi CT, Lemos AP, Brandt ME, Whitney AM, Melles CE, Solari CA, Frasch CE, Mayer LW.

Clin Diagn Lab Immunol. 1998 Nov;5(6):845-55.

40.

The use of oligonucleotide probes for meningococcal serotype characterization.

Sacchi CT, de Lemos AP, Whitney AM, Melles CE, Solari CA, Frasch CE, Mayer LW.

Rev Inst Med Trop Sao Paulo. 1998 Mar-Apr;40(2):113-7.

PMID:
9755566
41.

Meningococcal disease caused by Neisseria meningitidis serogroup B serotype 4 in São Paulo, Brazil, 1990 to 1996.

Sacchi CT, de Lemos AP, Camargo MC, Whitney AM, Melles CE, Solari CA, Frasch CE, Mayer LW.

Rev Inst Med Trop Sao Paulo. 1998 Mar-Apr;40(2):65-70.

PMID:
9755558
42.

The immunogenicity of Haemophilus influenzae type b conjugate vaccines in children born to human immunodeficiency virus-infected women. Women and Infants Transmission Study Group.

Read JS, Frasch CE, Rich K, Fitzgerald GA, Clemens JD, Pitt J, Pelton SI, Hanson IC, Handelsman E, Diaz C, Fowler MG.

Pediatr Infect Dis J. 1998 May;17(5):391-7.

PMID:
9613652
43.

Correlation between serological and sequencing analyses of the PorB outer membrane protein in the Neisseria meningitidis serotyping system.

Sacchi CT, Lemos AP, Whitney AM, Solari CA, Brandt ME, Melles CE, Frasch CE, Mayer LW.

Clin Diagn Lab Immunol. 1998 May;5(3):348-54.

45.

Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.

Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, Arhin FF, Devi SJ, Frasch CE, Huang JC, Kriz-Kuzemenska P, Lemmon RD, Lorange M, Peeters CC, Quataert S, Tai JY, Carlone GM.

Clin Diagn Lab Immunol. 1997 Mar;4(2):156-67.

47.

Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.

Devi SJ, Zollinger WD, Snoy PJ, Tai JY, Costantini P, Norelli F, Rappuoli R, Frasch CE.

Infect Immun. 1997 Mar;65(3):1045-52.

48.

Human immune response to epitopes on the meningococcal outer membrane class 5 protein following natural infection.

Danelli MG, Alves CM, Bastos RC, Batoreu NM, Barroso DE, Peralta JM, Frasch CE.

FEMS Immunol Med Microbiol. 1996 Sep;15(2-3):159-68.

PMID:
8880142
49.
50.

Antibody studies in mice of outer membrane antigens for use in an improved meningococcal B and C vaccine.

Milagres LG, Cristina M, Brandileone MC, Sacchi CT, Vieira VS, Zanella RC, Frasch CE.

FEMS Immunol Med Microbiol. 1996 Jan;13(1):9-17.

PMID:
8821393

Supplemental Content

Loading ...
Support Center